Business Context and Reporting Period
Karyopharm Therapeutics Inc. (KPTI) filed a Current Report on Form 8-K dated March 24, 2026. The filing discloses a private placement of equity securities, topline results from the pivotal Phase 3 SENTRY trial for myelofibrosis, an update on the Phase 3 XPORT-EC-042 trial for endometrial cancer, and a voluntary withdrawal of the accelerated approval for the Diffuse Large B-Cell Lymphoma (DLBCL) indication of XPOVIO (selinexor).
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: The Company entered into a Securities Purchase Agreement with RA Capital Management for gross proceeds of approximately $30 million at closing. This includes the sale of 1,030,354 shares of common stock at $6.785 per share and pre-funded warrants for 3,391,164 shares at $6.7849 per warrant.
- Additional Potential Proceeds: The placement includes warrants to purchase 4,421,518 shares at an exercise price of $10.00 per share, which could generate an additional $44 million if fully exercised.
- ATM Proceeds: In March 2026, the Company sold 1,100,844 shares under its At-The-Market (ATM) Sale Agreement for net proceeds of approximately $9.6 million.
- Debt and Liquidity: The closing of the Private Placement satisfies the capital raise trigger required to make effective the Second Amendment to the Credit and Guaranty Agreement and the Forbearance Agreement with lenders and noteholders. The filing does not provide specific current cash balances, total debt figures, or operating margins.
Material Changes and Clinical Developments
- SENTRY Trial (Myelofibrosis): The Phase 3 trial met its first co-primary endpoint. The combination of selinexor plus ruxolitinib demonstrated a statistically significant improvement in spleen volume reduction (SVR35) compared to ruxolitinib alone (50% vs. 28% at week 24; p<0.0001). The second co-primary endpoint (symptom improvement) was not statistically significant. A promising overall survival signal was observed (Hazard Ratio 0.43).
- DLBCL Indication Withdrawal: The Company agreed to voluntarily withdraw the accelerated approval of XPOVIO for DLBCL following an FDA request due to the inability to complete the confirmatory trial. The Company will cease clinical development and operational expenses for this indication. Management stated this is not due to safety concerns and revenue from this indication is immaterial.
- Endometrial Cancer: Topline data for the Phase 3 XPORT-EC-042 trial is expected in mid-2026.
Guidance, Outlook, and Risks
- Regulatory Path: The Company plans to meet with the FDA to discuss the SENTRY trial data and its supplemental new drug application (sNDA) filing plan. Potential inclusion in relevant compendia is expected in the second half of 2026.
- Use of Proceeds: Funds from the Private Placement will be used for general corporate purposes, including ongoing and planned clinical trial activities.
- Risks and Contingencies: The withdrawal of the DLBCL approval eliminates a potential revenue stream, though described as immaterial. The success of the company's future pipeline depends on the FDA's acceptance of the SENTRY data and the results of the upcoming endometrial cancer trial. The Private Placement is subject to customary closing conditions.
Investor Verification Checklist
- Verify the closing date and final net proceeds of the $30 million Private Placement.
- Confirm the specific timeline for the FDA meeting regarding the SENTRY trial sNDA filing.
- Review the full safety profile and discontinuation rates from the SENTRY trial (15% discontinuation rate in the combination arm vs. 9% in control).
- Monitor the status of the Forbearance Agreement and Credit Agreement now that the capital raise trigger has been satisfied.
- Track the mid-2026 data readout for the Phase 3 XPORT-EC-042 endometrial cancer trial.